{Reference Type}: Journal Article
{Title}: Can Semaglutide offer hope for patients with obesity-related heart failure?
{Author}: Olatunji G;Aderinto N;Kokori E;Ogieuhi IJ;Abraham IC;Olanisa O;Nebuwa C;Awoyinfa M;Ajimotokan O;Ajayi JO;Rao NN;Temidayo AO;Napoleon T;Samuel O;Ezeano C;
{Journal}: Curr Probl Cardiol
{Volume}: 49
{Issue}: 9
{Year}: 2024 Jun 11
{Factor}: 16.464
{DOI}: 10.1016/j.cpcardiol.2024.102697
{Abstract}: Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge with limited treatment options. This review explores the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for HFpEF treatment. Studies suggest promising benefits, including symptom improvement, weight management, and the potential for enhanced exercise capacity. However, the evidence for semaglutide's impact on exercise capacity and heart function remains inconclusive, and its anti-inflammatory effects require further investigation. The safety profile appears favorable, with gastrointestinal side effects being the most common adverse events. It is crucial to emphasize that additional research with longer follow-up, head-to-head comparisons, and exploration of optimal dosage and mechanisms of action are necessary to solidify semaglutide's role in HFpEF treatment. Semaglutide is promising to improve symptoms, promote weight loss, and potentially influence underlying HFpEF mechanisms. Future research can refine treatment strategies and unlock the full potential of semaglutide for this patient population.